# Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

> **NCT03024216** · PHASE1 · COMPLETED · sponsor: **University of Hawaii** · enrollment: 37 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** Atezolizumab1200 mg IV
- **DRUG:** Sipuleucel-T

## Key facts

- **NCT ID:** NCT03024216
- **Lead sponsor:** University of Hawaii
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-06
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2021-05-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03024216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03024216, "Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03024216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*